Product Information
CLINDA-TRETINOIN 1.2%-0.025% is a generic product labeled by Actavis Pharma, Inc., priced at $4.3119 per GM under NDC 00472179030. Its NADAC has been published 334 times since Oct 18, 2017.
FDA first approved this application on Jun 12, 2015. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
12; .25 mg/g; mg/g
Manufacturer
Actavis Pharma, Inc.NDC
00472179030
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
CLINDAMYCIN PHOSPHATE; TRETINOINApproval Type
Generic (ANDA)
FDA Application
ANDA202564FDA Approved
6/12/2015
TE Code
AB1
On Market Since
7/5/2016
Pharmacological Classes
Price Statistics
The NADAC for CLINDA-TRETINOIN 1.2%-0.025% has been published 334 times since Oct 18, 2017, and over the history we have for it it has declined 57.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.3119 per GM |
|---|---|
| All-time high | $10.0889 (Oct 16, 2019) |
| All-time low | $4.3119 (Sep 23, 2026) |
| 52-week high | $4.9717 |
| 52-week low | $4.3119 |
| Median price | $6.2350 |
| Average price | $7.0327 |
| Largest weekly change | -40.9% (May 18, 2022) |
| Weeks tracked | 334 |
| Tracking since | Oct 18, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 19% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin Phosphate and Tretinoin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLINDA-TRETINOIN 1.2%-0.025%?
The current National Average Drug Acquisition Cost (NADAC) for CLINDA-TRETINOIN 1.2%-0.025%, manufactured by Actavis Pharma, Inc., is $4.3119 per GM (NDC 00472179030), effective Sep 30, 2026.
How has the price of CLINDA-TRETINOIN 1.2%-0.025% changed over time?
Over the history we have for it, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has declined 57.1%. It has been tracked across 334 weekly CMS publications since Oct 18, 2017.
What are the highest and lowest recorded NADAC prices for CLINDA-TRETINOIN 1.2%-0.025%?
Since Oct 18, 2017, the NADAC for CLINDA-TRETINOIN 1.2%-0.025% has ranged from a low of $4.3119 (Sep 23, 2026) to a high of $10.0889 (Oct 16, 2019), with a median of $6.2350 per GM.
Are there cheaper alternatives to CLINDA-TRETINOIN 1.2%-0.025%?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CLINDA-TRETINOIN 1.2%-0.025%, is $3.5063 per GM — about 19% below CLINDA-TRETINOIN 1.2%-0.025%.
Who manufactures CLINDA-TRETINOIN 1.2%-0.025%?
CLINDA-TRETINOIN 1.2%-0.025% (NDC 00472179030) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.